Physiological Effects of Nebulized Salbutamol in Acute Respiratory Failure Patients on HFNC
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-90
SponsorUniversità degli Studi di Ferrara
About this trial
This is a prospective physiological interventional study that assess the feasibility and safety of administering salbutamol using a vibrating mesh nebulizer during HFNC in patients with acute hypoxemic respiratory failure (AHRF). We evaluate whether this method of salbutamol delivery can reduce inspiratory effort and improve global and regional lung ventilation in AHRF patients. To achieve this, the study will record and analyze the following: esophageal pressure (Pes) curves, global and regional tidal volumes, minute ventilation, and changes in global and regional lung ventilation assessed through Electrical Impedance Tomography (EIT).
Eligibility criteria
Qualifiers
• Age > 18, < 90 years
Non-intubated critically ill patients with AHRF due to pneumonia (diagnosis is based on the presence of infiltrates on chest X-ray and the onset of clinical signs of infection less than 7 days earlier)
PaO2/FiO2 ≤ 300 mmHg
Patients receiving oxygen therapy
Disqualifiers
• Age < 18 years
Hypercapnia (PaCO2 > 50 mmHg)
Hemodynamic instability (Systolic blood pressure < 90 mmHg or Mean arterial pressure < 60 or high dose of vasoactive drugs)
Tachycardia or tachyarrhythmia (HR > 130 b/min)
Trial design
Treatments tested in this trial
- salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Università degli Studi di Ferrara
Lead sponsor
Aerogen
Collaborator
Source ClinicalTrials.gov